Peginterferon-A-2B plus ribavirin is more effective than peginterferon-A-2A plus ribavirin in menopausal women with chronic hepatitis C

E. Villa, C. Cammà, A. Di Leo, A. Karampatou, M. Enea, S. Gitto, V. Bernabucci, L. Losi, N. De Maria, B. Lei, A. Ferrari, R. Vukotic, P. Vignoli, M. Rendina, A. Francavilla

Research output: Contribution to journalArticle

Abstract

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800-1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-IFNα-2a-treated patients and in 51.2% of Peg-IFNα-2b-treated patients (intention-to-treat; P = 0.139). Age, fibrosis stage and genotype 2 and 3 were independently associated with SVR by multivariate analysis. Analysing by gender, the difference in SVR between PEG-IFNα types was not significant in men but highly significant in women (Peg-IFNα-2a:39.1%vs Peg-IFNα-2b:54.4%, P = 0.007). This was attributable to a higher SVR rate with Peg-IFNα-2b in the difficult postmenopausal population (26.9% Peg-IFNα-2a vs 46.0% Peg-IFNα-2b, P = 0.040). In women, absence of menopause, genotype 2 hepatitis C virus infection and use of Peg-IFNα-2b were independently associated with SVR. In conclusion, predictive factors for SVR are different in men and women. Factors differing between genders are menopause, severe steatosis and peg-interferon used. The higher SVR rate with Peg-IFNα-2b in menopausal women is likely attributable to more favourable pharmacokinetics that allows Peg-IFNα-2b to reach visceral fat and oppose the increased cytokine production and enhanced inflammatory status in menopause.

Original languageEnglish
Pages (from-to)640-649
Number of pages10
JournalJournal of Viral Hepatitis
Volume19
Issue number9
DOIs
Publication statusPublished - Sep 2012

Keywords

  • central fat distribution
  • cytokines
  • metabolic syndrome
  • pharmacokinetics
  • sustained virological response

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Peginterferon-A-2B plus ribavirin is more effective than peginterferon-A-2A plus ribavirin in menopausal women with chronic hepatitis C'. Together they form a unique fingerprint.

  • Cite this

    Villa, E., Cammà, C., Di Leo, A., Karampatou, A., Enea, M., Gitto, S., Bernabucci, V., Losi, L., De Maria, N., Lei, B., Ferrari, A., Vukotic, R., Vignoli, P., Rendina, M., & Francavilla, A. (2012). Peginterferon-A-2B plus ribavirin is more effective than peginterferon-A-2A plus ribavirin in menopausal women with chronic hepatitis C. Journal of Viral Hepatitis, 19(9), 640-649. https://doi.org/10.1111/j.1365-2893.2012.01593.x